[
    [
        {
            "time": "2023-10-15",
            "original_text": "Evaluating Datadog, Toll Brothers, Bank of America, Cathay General Bancorp, Recro Pharma, IBM",
            "features": {
                "keywords": [
                    "Datadog",
                    "Toll Brothers",
                    "Bank of America",
                    "Cathay General Bancorp",
                    "Recro Pharma",
                    "IBM"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "real estate",
                    "finance",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Evaluating Datadog, Toll Brothers, Bank of America, Cathay General Bancorp, Recro Pharma, IBM",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]